INTRODUCTION
Prion-related encephalopathies are a group of neurodegenerative diseases that recognize, as etiopathologic agent, an aberrant isoform of the prion protein (PrP C ), named PrP Sc , from scrapie (Prusiner, 1998) . While PrP C is rapidly catabolized into the cell, PrP Sc is only partially degraded by proteases originating a protease-resistant core with a molecular mass of 27-30 kDa (PrP 27-30). PrP 27-30 polymerizes into rodshaped fibrils and accumulates in the nervous tissue with a pattern that is temporally and topographically associated with neuronal loss and astrogliosis (DeArmond, 1988) . The neuronal death that characterizes the prion encephalopathies, and other neurological disorders as well, is triggered by the activation of the apoptotic program (Stefanis, 1997; Gray, 1999) . Although in the past few years a large number of data has been produced to better characterize the molecular mechanisms involved in the conversion of PrP C in PrP Sc (Prusiner, 1998) , the intracellular signaling responsible for the PrP Sc -induced cell death is yet almost unknown. Many pathogenic characteristics of PrP Sc have been identified in a peptide corresponding to residues 106 -126 of PrP (PrP106 -126) (Tagliavini, 1993 ). PrP106 -126 shows a high tendency to adopt a ␤-sheet structure and to form amyloid fibrils in vitro (Tagliavini, 1993; De Gioia, 1994; Rymer, 2000) and is partially resistant to proteolysis (Selvaggini, 1993) . Moreover, the peptide was reported to induce apoptotic neuronal death in primary cultures of cortical, hippocampal, and cerebellar neurons (Forloni, 1993;  
